antibody

BRD4

MBS126660

0.05 mL

200 USD

polyclonal

rabbit

nonconjugated

western blot, immunohistochemistry, immunocytochemistry

Antibody

BRD4

[BRD4]

[BRD4]

[bromodomain-containing protein 4 isoform short; Bromodomain-containing protein 4; bromodomain-containing protein 4; bromodomain-containing 4; chromosome-associated protein; bromodomain containing 4; Protein HUNK1]

[BRD4; BRD4; CAP; MCAP; HUNK1; HUNKI; HUNK1]

BRD4_HUMAN

Polyclonal

IgG

Rabbit

Human, mouse, rat

722

Affinity Purification

Store at -20°C or -80°C. Avoid freeze / thaw cycles.

Western Blot (WB), Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Recommended Dilutions:. WB 1 :500 - 1 :2000. IHC 1:50-1:200. ICC 1:100-1:250

Western Blot (WB)

Buffer: PBS with 0.02% sodium azide, 50% glycerol, pH7.3.

Bromodomain-containing protein 4 (BRD4) is a member of the bromodomairls and extraterminal (BET) family of proteins, which also includes BRD2, BRD3, and BRDT (1-3). BET family proteins contain two tandem bromodomains and an extra terminal (ET) domain, and bind acetyl lysine residues (3). BRD4 is a chromatin-binding protein with a preference for Lys14 on histone H3 as well as Lys5 and Lys12 on histone H4 (4). BRD4 chromatin binding occurs throughout the cell cycle, including condensed mitotic chromosomes, when the majority of genes are silenced (5). DRD4 tlssocia::oll with chromatin uuring mitosis is thought to be an important part of the bookmarking mechanism to accelerate re-activation of the silenced genes upon exit from mitosis (2,6). BRD4 has been shown to facilitate transcription by recruiting the positive transcription elongation factor b (pTEFb) complex that phosphorylates Ser2 of the heptapeptide repeat of the C-terminal domain of RNA polymerase II, promoting transcription elongation (3,7,8). In addition, BRD4 has been found to be part of the super elongation complex and the polymerase associated factor complex (PAFc) in MLL-fusion derived leukemia cell lines, demonstrating a role for BRD4 in the regulation of transcription elongation (9). Research studies have shown that BRD4 (and BET family proteins) may be promising theraeupic targets for various Myc-driven cancers, such as Burkitt's lymphoma and certain acute myeloid leukemias (1,10,11). Investigators have found molecular inhibition of BET proteins to be effective in inducing apoptosis in various MLL-fusion driven leukemic cell lines by competing BRD3 and BRD4 from chromatin, leading to reduced expression of BcI-2, Myc, and CDK6 (9). BET inhibition has also been shown to have antitumor activities against nuclear protein in testis (NUT) midline carcinoma cell lines and xenografts in mice where BRD4 is found to be a frequent translocation partner of the NUT protein (12). In addition, BRD4 regulates the expression of some inflammatory genes, and inhibition of BRD4 (and BET family proteins) chromatin binding causes reduced expression of a subset of inflammatory genes in macrophages, leading to protection against endotoxic shock and sepsis (13).

7657218

NP_055114.1

NM_014299.2

O60885

152kDa

0.05 mL

200 USD

0.1 mL

275

0.2 mL

430